G-CON Manufacturing Launches Transmissible Disease Containment POD - - BioPharm International


G-CON Manufacturing Launches Transmissible Disease Containment POD

G-CON Manufacturing launched a transmissible disease containment (TDC) POD, the latest of its modular, autonomous cleanroom production structures. The TDC POD differs from the typical G-CON Manufacturing POD in width (8.5 feet), such that it is easily transported by tractor-trailer or its own axle system. The TDC PODs also have double bag-in/bag-out HEPA filters and will be equipped with their own generator units. All POD structures are readily deployable containment and cleanroom systems that include their own air handling systems and cleanable epoxy internal surfaces. All PODs can be cleaned with a number of methods, including vaporized hydrogen peroxide (VHP) or chlorine dioxide. Prefabricated PODs are typically built in 18 weeks. Integrated air bearings make additional support equipment unnecessary upon delivery.

"All our current POD systems already serve as either cleanroom environments and/or biosafety-level (BSL) containment systems," explained Maik Jornitz, president of G-CON Manufacturing, in a press release. "However, in light of recent events, we realized the need for even faster deployment and even better containment with redundancy functions in a transmissible disease application. The available alternatives are simply not robust enough, lack scaling capabilities, and cannot be properly sanitized for repeated uses. Each POD can hold a number of patients and equipment in a larger area, are easily deployable due to their robust aluminum structure, and represent the optimal containment due to redundant air filters. Moreover, available integrated VHP or other methodologies make cleaning as simple as pressing a button."

Source: G-CON Manufacturing

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here